Pharmaceuticals, Biotechnology and Life Sciences
Arrowhead Pharmaceuticals have announced participating in several conferences in October, covering cystic fibrosis, Oligonucleotide-Based Therapeutics, and genetic medicines topics.
FDA has approved Invokana (canagliflozin) to treat diabetic kidney disease (DKD) and reduce the risk of hospitalization for heart failure in patients with type 2 diabetes (T2D) and DKD, which is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart failure in patients with T2D and DKD.
Lysogene posted net loss, for the first half of 2019 which amounted to €1.9 million compared to €7.2 million in the first half of 2018, with €6.8 million revenues in the first half 2019.
Startup Sandbox graduates are poised to deliver breakthroughs with global impact with innovation spanning next-generation DNA sequencing, drug discovery, and cancer screening to bioceramics, biofoam, and smart gardening.
Transgene posted promising result at ESMO, of TG4001 plus Bavencio (avelumab) in HPV-16 positive cancers, from a clinical trial conducted…
AstraZeneca and Merck’s LYNPARZA reduced the risk of disease progression or death by 51% in men with homologous recombination repair…
-Pulmotect, Inc., a clinical-stage biotechnology company developing drugs that harness the power of the immune system to fight a wide range of respiratory diseases, is pleased to announce Colin Broom, MD, has joined the company as Chief Executive Officer.
– 22% Response Rate; 61% Disease Control Observed – REHOVOT, Israel & WILMINGTON, Del.–(BUSINESS WIRE)–Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical…
KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Michael Nally,…
Alvotech said in a Monday press release it has appointed Joseph Edward McClellan as its new Chief Scientific Officer, who will be leading the company’s R&D functions, with overall responsibility for bringing products to market through its pipeline and overseeing R&D operations across Alvotech’s sites in Reykjavik, Julich, Hanover and Zurich.